<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683462</url>
  </required_header>
  <id_info>
    <org_study_id>TC-1734-226-CRD-005</org_study_id>
    <nct_id>NCT00683462</nct_id>
    <nct_alias>NCT00683215</nct_alias>
  </id_info>
  <brief_title>An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will
      be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with
      DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping
      will be completed at screening and slow metabolisers will be excluded from participation in
      this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made
      during each treatment period. Safety and tolerability assessments will be a major component
      of the trial and all serious adverse events (SAE) will be immediately (within 24 hours)
      reported to both Targacept and to AstraZenca.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Total Symptoms Scale Score (of ADHD) of the Connors Adult ADHD Rating Scale-Investigator Rating (CAARS-INV).</measure>
    <time_frame>Visit 1, 2, 3, 4, 5, 8, 9, 10,13, 14 and 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scales (NIMH 1985)</measure>
    <time_frame>Visit 1, 2, 3, 4, 5, 8, 9, 10, 13, 14,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR computerized cognitive battery</measure>
    <time_frame>2, 3, 5, 8, 10, 13, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNRU computerized cognitive battery</measure>
    <time_frame>2, 3, 5, 8, 10, 13, 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>Capsules 5 mg/day (once a day) for 2 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>Capsules 50 mg/day (once a day) for 2 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of DSM-IV ADHD

          -  Score of equal or more than 2 on at least six of nine items in at least one of the
             subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV)

          -  Score of equal or more than 4 (at least moderate severity) on the Clinical Global
             Impressions-Severity (CGI-S) test

        Exclusion Criteria:

          -  Current DSM-IV Axis I psychiatric disorder (other than ADHD)

          -  Current user of cigarettes or other nicotine-containing product.

          -  Slow metabolizers as indicated by CYP2D6 genotyping.

          -  Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or
             intended use during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>October 29, 2009</last_update_submitted>
  <last_update_submitted_qc>October 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hans-Göran Hårdemark, MD, PhD, Medical Science Director AZD3480</name_title>
    <organization>AstraZeneca R&amp;D, Södertälje</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 4, 2016</submitted>
    <returned>February 2, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

